JP2005531516A5 - - Google Patents

Download PDF

Info

Publication number
JP2005531516A5
JP2005531516A5 JP2003575963A JP2003575963A JP2005531516A5 JP 2005531516 A5 JP2005531516 A5 JP 2005531516A5 JP 2003575963 A JP2003575963 A JP 2003575963A JP 2003575963 A JP2003575963 A JP 2003575963A JP 2005531516 A5 JP2005531516 A5 JP 2005531516A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
prodrug
alkoxy
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003575963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531516A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/000844 external-priority patent/WO2003077910A1/en
Publication of JP2005531516A publication Critical patent/JP2005531516A/ja
Publication of JP2005531516A5 publication Critical patent/JP2005531516A5/ja
Withdrawn legal-status Critical Current

Links

JP2003575963A 2002-03-18 2003-03-06 選択的ep4受容体アゴニストによる治療方法 Withdrawn JP2005531516A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36571102P 2002-03-18 2002-03-18
PCT/IB2003/000844 WO2003077910A1 (en) 2002-03-18 2003-03-06 Methods of treatment with selective ep4 receptor agonists

Publications (2)

Publication Number Publication Date
JP2005531516A JP2005531516A (ja) 2005-10-20
JP2005531516A5 true JP2005531516A5 (cg-RX-API-DMAC10.html) 2006-03-23

Family

ID=28042041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003575963A Withdrawn JP2005531516A (ja) 2002-03-18 2003-03-06 選択的ep4受容体アゴニストによる治療方法

Country Status (12)

Country Link
US (1) US7414071B2 (cg-RX-API-DMAC10.html)
EP (1) EP1487437B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005531516A (cg-RX-API-DMAC10.html)
AT (1) ATE336247T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003207900A1 (cg-RX-API-DMAC10.html)
BR (1) BR0308738A (cg-RX-API-DMAC10.html)
CA (1) CA2478653A1 (cg-RX-API-DMAC10.html)
DE (1) DE60307607T2 (cg-RX-API-DMAC10.html)
ES (1) ES2268327T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA04005555A (cg-RX-API-DMAC10.html)
TW (1) TW200304816A (cg-RX-API-DMAC10.html)
WO (1) WO2003077910A1 (cg-RX-API-DMAC10.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
WO2004065365A1 (ja) * 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. 8−アザプロスタグランジン誘導体およびその医薬用途
US6734206B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
JP2007512347A (ja) * 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
CA2569464C (en) * 2004-06-04 2012-10-23 Allergan, Inc. 5-thio-piperdinyl prostaglandin e analogs
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2006052893A2 (en) 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
US7674786B2 (en) 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
WO2006121822A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
CA2602535A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. Substituted beta-lactams and their use in medicine
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2269611B1 (en) 2006-11-16 2016-03-23 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
JP5069752B2 (ja) 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ep4受容体アゴニストとしてのベンズアミド誘導体
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
EP2875022B1 (en) 2012-07-19 2016-10-12 Cayman Chemical Company, Incorporated Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2014144500A2 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
PT2989098T (pt) 2013-03-15 2017-08-16 Cayman Chemical Co Inc Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
HUE035698T2 (en) 2013-12-17 2018-05-28 Lilly Co Eli Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator
US9540357B1 (en) * 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
CN114259992B (zh) * 2021-12-23 2023-06-27 复旦大学 正离子超分子有机框架固体材料在吸附生物毒素中的应用
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113873A (en) * 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
DE2528664A1 (de) * 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
CA1077948A (en) * 1976-08-06 1980-05-20 Albin J. Nelson 1,-5 disubstituted-2-pyrrolidones and processes for their production
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US6545045B1 (en) * 1998-12-24 2003-04-08 Alcon Manufacturing, Ltd. Prostaglandin E agonists for treatment of glaucoma
AU2001290250A1 (en) * 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
EA200300379A1 (ru) * 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension

Similar Documents

Publication Publication Date Title
CN100430052C (zh) 组织蛋白酶半胱氨酸蛋白酶抑制剂
CA2565813A1 (en) Substituted methyl aryl or heteroaryl amide compounds
WO2006098918B1 (en) Substituted gamma lactams as therapeutic agents
HRP20161371T1 (hr) Modulatori farmakokinetičkih svojstava terapeutika
JP2011511840A5 (cg-RX-API-DMAC10.html)
JP2008513516A5 (cg-RX-API-DMAC10.html)
JP2006515587A5 (cg-RX-API-DMAC10.html)
JP2009524675A5 (cg-RX-API-DMAC10.html)
JP2007513915A5 (cg-RX-API-DMAC10.html)
JP2008513498A5 (cg-RX-API-DMAC10.html)
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
RU2002131639A (ru) Ингибиторы дипептидилпептидазы iv
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
JP2009538897A5 (cg-RX-API-DMAC10.html)
WO2016081649A1 (en) Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
JP2002523400A5 (cg-RX-API-DMAC10.html)
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
CA2398794A1 (en) 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
JP2014530881A5 (cg-RX-API-DMAC10.html)
SI2315587T1 (en) A therapeutic composition comprising macitentan
PE20060602A1 (es) Derivados de heteroaril acil pirrolidina como inhibidores del virus de la hepatitis c (hcv)
IL188095A0 (en) Substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides, their use as kv1.5 potassium channel blockers and pharmaceutical preparations comprising them
US20080234337A1 (en) Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
EP1586564A1 (en) 8-azaprostaglandin derivatives and medicinal uses thereof